Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 7/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640753 | 1.00 | L3MBTL1 (0.42) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL21964495 | 1.00 | L3MBTL1 (0.42) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL13384038 | 0.89 | L3MBTL1 (0.45) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL15820474 | 0.82 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL15820472 | 0.82 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16640754 | 0.81 | FUCA1 (0.38) | — | |
| SCHEMBL18251216 | 0.80 | L3MBTL1 (0.47) | L3MBTL1MAPTLGALS1LGALS3LGALS9 | |
| SCHEMBL23848882 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14028866 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL8347365 | 0.79 | GBA1 (0.46) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | L3MBTL1 1778/4885MAPT 1804/4885LGALS1 824/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | L3MBTL1 1526/4885MAPT 1857/4885LGALS1 582/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | L3MBTL1 1356/4885MAPT 2065/4885LGALS1 565/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | L3MBTL1 1526/4885MAPT 1857/4885LGALS1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.